Company Profile
ADMA Biologics Stock Price, News & Catalysts
- Ticker:
- ADMA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.95 USD (+0.56%)
Close
Last updated: September 17, 2026
1.76B USD
Market cap
Why the stock is moving
As of Sep 17, 2026, ADMA closed up 0.56% at $8.95. No new same-company headline was identified in the current news window.
Company overview
Plasma-Derived Biologics
ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection.
ASCENIV
ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for patients with primary humoral immunodeficiency, including complex later-line cases.
BIVIGAM and Manufacturing
BIVIGAM is a standard intravenous immunoglobulin product. ADMA controls plasma collection, fractionation, manufacturing and commercialization, allowing the company to manage supply and product mix internally.
SG-001
SG-001 is a pneumococcal hyperimmune-globulin development program intended to use ADMA's existing plasma, manufacturing and commercial infrastructure for an infectious-disease product.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ADMA Biologics (ADMA)?
ADMA Biologics (ADMA) most recently closed at 8.95 USD, a +0.56% move versus the previous session.
What is the market cap of ADMA Biologics (ADMA)?
ADMA Biologics currently has a market capitalization of 1.76B USD on BioPharmSignal.
What does ADMA Biologics do?
Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection. ASCENIV ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for patients with primary...
On which exchange is ADMA stock listed?
ADMA Biologics (ADMA) is associated with NASDAQ, United States, Biopharma.
What is SG-001?
SG-001 SG-001 is a pneumococcal hyperimmune-globulin development program intended to use ADMA's existing plasma, manufacturing and commercial infrastructure for an infectious-disease product.
Which conditions is ADMA Biologics targeting with SG-001?
ADMA Biologics is associated with respiratory disease based on its company overview and current catalyst commentary.
What is Plasma-Derived?
Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S.
What is Biologics?
Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S.